“Venky’s 37% Crash & The Poultry Paradox: Chicken Empire Lays Golden Eggs but Eats Its Own Margins”
1. At a Glance
Venky’s (India) isn’t just selling chicken—it’s selling drama. From broiler birds that bulk up faster than gym bros on steroids to oilseed margins that collapse harder than a crypto exchange, this ₹2,064 crore market cap poultry czar has been serving investors one thing consistently: indigestion. The stock is down 37% in a year, operating margins are thin like papad, and yet promoters still hold a fat 56%. When your birds are growing faster than your profits, you know the math is scrambled.
2. Introduction
Venky’s (India) Ltd, part of the VH Group, is the undisputed godfather of Indian poultry. They breed chickens, sell day-old chicks, manufacture feed supplements, and run an oilseed business for that protein punch. On paper, this looks like a vertically integrated empire—“farm-to-fork,” as consultants like to pitch. In reality? It’s “farm-to-fight,” with every segment battling commodity volatility, government policy mood swings, and festivals like Kumbh Mela (yes, even godmen fasting dent chicken sales).
The stock once had the swagger of a FMCG prince but has lately behaved more like an unvaccinated bird flu carrier. Sales growth over five years? A miserable 0.28%. Profits have shrunk faster than ice cream in Nagpur heat. And investors? They’ve been treated like customers at a shady dhaba—served stale chicken and overcharged.
But here’s the kicker: Venky’s has pockets of strength. The animal health business is growing, the ready-to-eat chicken segment has doubled volumes, and SPF eggs are riding the vaccine boom. It’s like watching a dysfunctional joint family drama—some cousins are making money, while others are burning it at the poker table.
So the question for readers: is Venky’s just a cyclical poultry soap opera, or is this chicken finally learning to fly?
3. Business Model – WTF Do They Even Do?
Imagine a buffet plate with too many items: chicken, eggs, soya, medicines, spices. That’s Venky’s.
Poultry & Poultry Products: The crown jewel. They breed broilers, sell day-old chicks (DOCs), produce SPF eggs (for vaccines), and run ready-to-eat chicken. This contributes ~60% of revenue but carries wild mood swings.
Animal Health Products (AHP): Think of this as the in-house pharmacy for chickens. Medicines, feed supplements, vaccines—the works. Growing steadily at ~9% annually, this is the nerdy cousin who doesn’t party but aces exams.
Oilseed Processing (Soya): The problem child. Once ₹2,600 crore in revenue, now halved. Why? Because ethanol blending birthed DDGS, a cheaper feed substitute that ate into soya DOC’s market share. Government policies add masala by flipping import duties like coin tosses.
New Experiments: Ready-to-cook chicken (targeting Swiggy moms and KFC bros) and spice mixes (because why not?). Early days, but at least it looks FMCG-ish on the slide deck.
So yes, Venky’s is part farmer, part pharma, part FMCG, part commodity trader—basically a desi Reliance Jio of chickens.
Question for you: would you rather bet on the chicken or the masala sprinkled on it?
4. Financials Overview
Metric
Latest Qtr (Jun’25)
YoY Qtr (Jun’24)
Prev Qtr (Mar’25)
YoY %
QoQ %
Revenue
₹866 Cr
₹808 Cr
₹843 Cr
7.2%
2.7%
EBITDA
₹24 Cr
₹103 Cr
₹25 Cr
-76.7%
-4.0%
PAT
₹15.8 Cr
₹75 Cr
₹13 Cr
-78.9%
21.5%
EPS (₹)
11.2
53.4
9.4
-79.0%
19.1%
Commentary: This table is like a badly fried omelette—burnt edges everywhere. Revenue grew 7%, but EBITDA collapsed 77%. PAT is a shadow of its former self. EPS at ₹11.2 annualizes to ₹45—giving you a P/E of 32x. For a business with margins thinner than airline idlis, that’s spicy.
5. Valuation – Fair Value Range Only
P/E Method: EPS TTM = ₹40.6. Industry P/E ~21. Fair Value = ₹850–₹1,100.
EV/EBITDA Method: EBITDA TTM = ₹92 Cr. EV = ₹2,045 Cr. → EV/EBITDA = 22x. Sector median ~12–14x. Fair Value EV = ₹1,100–₹1,300 Cr. → Equity Value per share ~₹750–₹950.
